Lots of good things with the call as I listen a second time. UK moving quickly. Lots of potential publications (not even counting Dr BPs paper). I can deal with the red tape the FDA and NASDAQ processes provide. CYDY can only give them what they ask for and hope for the best. One thing I did notice was the update Dr Kelly provided on the list of on going discussions. One country was noticeably absent...United States. Were the MM results not good enough for continued discussions with the big pharma previously mentioned? I would have preferred that question to the countless repeats of people trying to force cydy to guess an uplisting date and give timelines and set them up for potential failure of something they have no control over other than to respond and try to meet the qualifications.